-
Something wrong with this record ?
Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
T. Smutny, I. Barvik, T. Veleta, P. Pavek, T. Soukup,
Language English Country Switzerland
Document type Journal Article, Review
Grant support
00179906
MH CZ - DRO UHHK
PROGRES Q40-15, PROGRES Q47
Charles University research projects
[No. CZ.02.1.01/0.0/0.0/16_019/0000841] co-funded by ERDF
EFSA-CDN
NLK
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2019-01-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
Health & Medicine (ProQuest)
from 2019-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
PubMed
31035618
DOI
10.3390/jcm8050582
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
- Review MeSH
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related chronic inflammatory diseases. Glucocorticoids (GCs) are first-choice drugs for PMR and GCA, although some patients show poor responsiveness to the initial GC regimen or experience flares after GC tapering. To date, no valid biomarkers have been found to predict which patients are at most risk for developing GC resistance. In this review, we summarize PMR- and GCA-related gene polymorphisms and we associate these gene variants with GC resistance and therapeutic outcomes. A limited number of GC resistance associated-polymorphisms have been published so far, mostly related to HLA-DRB1*04 allele. Other genes such ICAM-1, TLR4 and 9, VEGF, and INFG may play a role, although discrepancies are often found among different populations. We conclude that more studies are required to identify reliable biomarkers of GC resistance. Such biomarkers could help distinguish non-responders from responders to GC treatment, with concomitant consequences for therapeutic strategy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19029062
- 003
- CZ-PrNML
- 005
- 20190823101607.0
- 007
- ta
- 008
- 190813s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/jcm8050582 $2 doi
- 035 __
- $a (PubMed)31035618
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Smutny, Tomas $u Department of Pharmacology and Toxicology, Centre for Drug Development, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. smutt6aa@faf.cuni.cz.
- 245 10
- $a Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis / $c T. Smutny, I. Barvik, T. Veleta, P. Pavek, T. Soukup,
- 520 9_
- $a Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related chronic inflammatory diseases. Glucocorticoids (GCs) are first-choice drugs for PMR and GCA, although some patients show poor responsiveness to the initial GC regimen or experience flares after GC tapering. To date, no valid biomarkers have been found to predict which patients are at most risk for developing GC resistance. In this review, we summarize PMR- and GCA-related gene polymorphisms and we associate these gene variants with GC resistance and therapeutic outcomes. A limited number of GC resistance associated-polymorphisms have been published so far, mostly related to HLA-DRB1*04 allele. Other genes such ICAM-1, TLR4 and 9, VEGF, and INFG may play a role, although discrepancies are often found among different populations. We conclude that more studies are required to identify reliable biomarkers of GC resistance. Such biomarkers could help distinguish non-responders from responders to GC treatment, with concomitant consequences for therapeutic strategy.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Barvik, Ivan $u Institute of Physics, Faculty of Mathematics and Physics, Charles University, 121 16 Prague, Czech Republic. ibarvik@karlov.mff.cuni.cz.
- 700 1_
- $a Veleta, Tomas $u Department of Emergency Medicine, University Hospital in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. tomas.veleta@fnhk.cz.
- 700 1_
- $a Pavek, Petr $u Department of Pharmacology and Toxicology, Centre for Drug Development, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. pavek@faf.cuni.cz.
- 700 1_
- $a Soukup, Tomas $u Division of Rheumatology, 2nd Department of Internal Medicine⁻Gastroenterology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic. soukutom@fnhk.cz.
- 773 0_
- $w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 8, č. 5 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31035618 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823101822 $b ABA008
- 999 __
- $a ind $b bmc $g 1434211 $s 1067522
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 8 $c 5 $e 20190427 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
- GRA __
- $a 00179906 $p MH CZ - DRO UHHK
- GRA __
- $a PROGRES Q40-15, PROGRES Q47 $p Charles University research projects
- GRA __
- $a [No. CZ.02.1.01/0.0/0.0/16_019/0000841] co-funded by ERDF $p EFSA-CDN
- LZP __
- $a Pubmed-20190813